- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17.12. | INCOG reveals $200m injectable drug expansion in Indiana | ||
| 16.12. | Sanofi signs pair of billion-dollar biotech deals to bolster pipeline | ||
| 16.12. | Pfizer trims 2026 profit forecast amid Covid headwinds and patent cliff pressures | ||
| 16.12. | LEO Pharma applies to EMA to expand Anzupgo use to adolescents | ||
| 16.12. | SK Capital Partners supports Swixx BioPharma's global expansion | ||
| 15.12. | J&J gains label expansion approval for Akeega in mCSPC | ||
| 15.12. | First gonorrhoea antibiotics in decades herald new era of treatment | ||
| 15.12. | Sanofi shares fall 6% after double setback for MS drug tolebrutinib | ||
| 15.12. | FDA approves Acadia's Daybue Stix for Rett syndrome | ||
| 15.12. | Sobi buys Arthrosi to expand gout treatment pipeline | ||
| 12.12. | EU inches closer to new pharma legislation amid competitiveness drive | ||
| 12.12. | China's NMPA approves Sanofi's rare haematologic disease treatments | ||
| 12.12. | Zealand Pharma and OTR to develop metabolic disease therapeutics | ||
| 11.12. | Novartis and UK-based Relation forge R&D deal worth up to $1.7bn | ||
| 11.12. | Moderna signs deal worth up to $503m with Nanexa | ||
| 11.12. | UK slashes 2026 drug rebate rate by one-third to win back pharma sentiments | ||
| 11.12. | Pfizer plans job cuts in Switzerland to reduce expenses | ||
| 11.12. | Boehringer's Jascayd gains China's NMPA approval for PPF | ||
| 11.12. | Formation Bio gains global rights to Lynk Pharma's TYK2 inhibitor | ||
| 10.12. | Cell and gene therapy investment strategy pivots as funding dries up | ||
| 10.12. | Eli Lilly picks Alabama as home to $6bn orforglipron manufacturing facility | ||
| 10.12. | Formycon and Zydus sign exclusive agreement for FYB206 supply | ||
| 10.12. | Health Canada approves Biogen's Zurzuvae for PPD treatment | ||
| 09.12. | BIOSECURE Act set for Congress vote after inclusion in annual defence bill | ||
| 09.12. | Mirum to buy Bluejay for up to $820m in rare liver disease push |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .